SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,608

Sector

Pharmaceuticals

Calendar

2025-03-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

income-statement-evolution-chart SHANGHAI-SHYNDEC-PHARMACE

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.17CNY

Average target price

19.52CNY

Spread / Average Target

+60.39%

Consensus

Profit revisions

estimates-change-chart SHANGHAI-SHYNDEC-PHARMACE

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SHANGHAI-SHYNDEC-PHARMACE

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2024-12-02			5-day change	1st Jan Change
12.17 ^CNY	-0.08%		+0.58%	+24.31%

Nov. 27	Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	MT
Nov. 27	Shanghai Shyndec Pharmaceutical CFO Resigns	MT

Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	Nov. 27	MT
Shanghai Shyndec Pharmaceutical CFO Resigns	Nov. 26	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	Oct. 28	CI
China Approves Shyndec Pharmaceutical's Listing Application for Epilepsy Drug Ingredient	Sep. 05	MT
Shyndec Pharmaceutical Gets Nod to Add Specification to Pravastatin Sodium Tablets	Aug. 30	MT
Shyndec Pharmaceutical's H1 Profit Soars 108%, Operating Income Slips 8%	Aug. 28	MT
Shyndec Pharmaceutical's Chairman, President Resign	Aug. 28	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 27	CI
Shanghai Shyndec Pharmaceutical Antibiotic Drug Passes Drug Consistency Evaluation	Aug. 12	MT
Shanghai Shyndec Pharmaceutical's Chest Pain Drug Passes China's Drug Evaluations	Jul. 31	MT
Shyndec Pharmaceutical's Unit Gets Nod to Amend Lipoic Acid Injection's Specification	Jul. 19	MT
Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	Jul. 12	MT
Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	Jul. 09	MT
Shyndec Pharma Unit Gets China Nod for Analgesic Ingredient	Jun. 14	MT
Shyndec Pharma Unit Gets China Nod for Conjunctivitis Eye Drops	Jun. 14	MT
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection	May. 15	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	Apr. 16	MT
China stocks rise after new guidelines; HK shares drop	Apr. 15	RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	Apr. 10	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	Mar. 27	MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine	Mar. 07	MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	Feb. 20	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	Feb. 20	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 25	CI

Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities